Neoplasms Clinical Trial
— MAGICOfficial title:
A Randomized, Controlled, Multi-center Collaborative Study to Evaluate the Efficacy of Magnesium Isoglycyrrhizinate Injection in the Prevention of Antineoplastic Chemotherapy Related Acute Liver Injury
This purpose of this study is to evaluate the evaluate the efficacy of Magnesium Isoglycyrrhizinate Injection in the prevention of antineoplastic chemotherapy related acute liver injury.
Status | Recruiting |
Enrollment | 2040 |
Est. completion date | August 2014 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Male or female aged 18-75 years; 2. Patients with malignant tumor accord with chemotherapy indication, candidate to a chemotherapy treatment, disease is not restricted; 3. Accorded with the following chemotherapy plan: included cis-platinum, =60mg/m2/course; included oxaliplatin, =85mg/m2/course; included cyclophosphamide, =600mg/m2/course; included gemcitabine, =60mg/m2/course; 4. ECOG=2; 5. Estimates survival time=3 months; 6. TBIL=1.0×ULN, ALT?AST=1.0×ULN; blood examination, uronoscopy, stool examination, renal function tests and electrocardiogram are normal; 7. Patients have been apart from the previous chemotherapy to finish above 2 weeks (including 2 weeks). Exclusion Criteria: 1. Patients with partial liver radiotherapy; 2. Hepatitis B or C virus replication in the state, the patient will need antiviral therapy; 3. Patients have serious heart diseases, liver kidney diseases, or metabolism function disorder; 4. Patients combined with cellular immune therapy; 5. Within 2 weeks of application or currently possible applications of drugs(polyene phosphatidylcholine, reduced glutathione, tiopronin and other hepatoprotective and choleretic drugs), interference with the study; 6. Pregnancy, or patients during breast feeding; 7. Patients have known hypersensitivity to Glycyrrhizin; 8. Patients are participating, or have participated in other Clinical studies of new drugs within 4 weeks. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
China | China PLA General Hospital | Beijing | Beijing |
China | The First Affiliated Hospital of General Hospital of PLA ( 304 ) | Beijing | Beijing |
China | Xiangya Hospital of Central South University | Changsha | Hunan |
China | Changzhou Second People's Hospital | Changzhou | Jiangsu |
China | Fujian Province-owned Hospital | Fuzhou | Fujian |
China | Fuzhou General Hospital of Nanjing Military Area Command | Fuzhou | Fujian |
China | Guangdong General Hospital | Guangzhou | Guangdong |
China | The First Affiliated Hospital of Guangzhou Medical College | Guangzhou | Guangdong |
China | Tumour Hospital Affiliated to Guangzhou Medical College | Guangzhou | Guangdong |
China | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | Hefei | Anhui |
China | The First Affiliated Hospital of Nanchang University | Nanchang | Jiangxi |
China | Nanjing General Hospital of Nanjing Military Area Command | Nanjing | Jiangsu |
China | The 81st hospital of PLA | Nanjing | Jiangsu |
China | The First Affiliated Hospital of Nanjing Medical University | Nanjing | Jiangsu |
China | The first hospital of Nanjing | Nanjing | Jiangsu |
China | The Second Affiliated Hospital of Nanjing Medical University | Nanjing | Jiangsu |
China | The Affiliated Tumor Hospital of Guangxi Medical University | Nanning | Guangxi |
China | The First Affiliated Hospital of Guangxi Medical University | Nanning | Guangxi |
China | Affiliated Hospital of Medical College of Qiingdao University | Qingdao | Shandong |
China | The first hospital of Hebei Medical University | Shijiazhuang | Hebei |
China | The second hospital of Hebei Medical University | Shijiazhuang | Hebei |
China | The people's Hospital of Wuhan University | Wuhan | Hubei |
China | The First Affiliated Hospital of Xinjiang Medical University | Wulumuqi | Xinjiang |
China | Wuxi Fourth People's Hospital | Wuxi | Jiangsu |
China | Wuxi People's Hospital | Wuxi | Jiangsu |
China | Affiliated Hospital of Xuzhou Medical College | Xuzhou | Jiangsu |
China | The First Affiliated Hospital of Zhengzhou University | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Cttq |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The incidence of liver injury | anyone of ALT?AST?ALP?TBIL?DBIL??-GT>ULN | 0-15 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Completed |
NCT03190811 -
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
|
Phase 1/Phase 2 |